[{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"EV104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"EV104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmune Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"EV-104","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EvolveImmune Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"EvolveImmune Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EvolveImmune Therapeutics","amount2":1.47,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"14","companyTruncated":"EvolveImmune Therapeutics \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by EvolveImmune Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration will leverage EvolveImmune’s T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : $65.0 million

                          October 31, 2024

                          Lead Product(s) : Antibody-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : AbbVie Inc

                          Deal Size : $1,465.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : EvolveImmune intends to use the proceeds to support continued platform and pipeline development including the advancement of its lead program, EV-104, a novel multi-functional T cell engager with integrated CD2 costimulation which conditionally targets U...

                          Brand Name : EV-104

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : EV-104

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Pfizer Ventures

                          Deal Size : $37.0 million

                          Deal Type : Financing

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims to evaluate the molecular MOA of EvolveImmune’s proprietary costimulatory T cell engager platform, EVOLVE, designed to unleash potent, selective, and integrated T cell costimulation to address unmet needs for the treatment of sol...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : University of Oxford

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : EVOLVE-104 (EV104), is a first-in-category therapeutic with potential to address a wide range of patients for the treatment of solid tumors with high selectivity.

                          Brand Name : EV104

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 24, 2022

                          Lead Product(s) : EV104

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          BMWS24
                          Not Confirmed
                          BMWS24
                          Not Confirmed

                          Details : EV104, includes cannabidiol (CBD) and celecoxib conjugate is a first-in-category therapeutic with potential to address a wide range of solid tumors with high selectivity.

                          Brand Name : EV104

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 18, 2022

                          Lead Product(s) : EV104

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank